CDKN2A and neoplasm: Another tumor had an A92S H3F3A mutation in addition to mutated ATRX. Somatic mutations in TP53 pathway genes (TP53, CREBBP, ATM, ATR, CDKN2A, and MDM2) were significantly enriched (P = 0.01) in ALT-positive tumors.